Research Article

Molecular Mechanism of Palmitic Acid on Myocardial Contractility in Hypertensive Rats and Its Relationship with Neural Nitric Oxide Synthase Protein in Cardiomyocytes

Haibo Tan,1 Weiwei Song,1 Sha Liu,1 Qing Song,1 Tiangang Zhou,2 Yidan Wang,2 and Yunfeng Hou2

1Department of Critical Care Medicine, Zibo Central Hospital, Zibo, 2553000 Shandong Province, China
2Department of Intensive Care Unit, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014 Shandong Province, China

Correspondence should be addressed to Yunfeng Hou; hyfmk1203@hotmail.com

Received 17 November 2020; Revised 9 March 2021; Accepted 3 April 2021; Published 14 April 2021

Academic Editor: Zhenbo Xu

Copyright © 2021 Haibo Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. It is aimed at investigating the mechanism of palmitic acid (PA) on myocardial contractility in hypertensive rats and its relationship with myocardial neural nitric oxide synthase (nNOS) protein.

Methods. The rats were randomly divided into sham operation group and hypertensive group, with thirty rats in each group, to prepare angiotensin II-induced hypertensive model rats. The blood pressure of rats was measured by the multianimal multichannel tail cuff noninvasive blood pressure system of Kent Coda, USA. The Ionoptix single-cell contraction detection system was used to detect myocardial cells. ATP level of left ventricular cardiomyocytes was determined by luminescence method, and protein was measured by Western blot.

Results. Compared with the sham group, systolic blood pressure and diastolic blood pressure were increased in the hypertensive group over 4 weeks; PA increased the contractility of left ventricular cardiomyocytes in normal rats, but not in hypertensive rats, and PA increased the intracellular ATP level of rats in the sham group but not in the hypertension group. In the hypertension group, the expression of nNOS in the cardiomyocytes was significantly increased, and specific nNOS inhibitor S-methyl-L-thiocitrulline (SMTC) was found to restore the positive inotropic effect of PA in the myocardium of the hypertension group. PA was supplemented after using CPT-1 inhibitor etomoxir (ETO); it was found that ETO inhibited the positive inotropic effect of PA on left ventricular cardiomyocytes in the sham group, and PA was supplemented after using SMTC and ETO, it was found that SMTC + ETO could inhibit the positive inotropic effect of PA on left ventricular cardiomyocytes in myocardium of hypertensive rats. Conclusion. PA could increase the contractility of healthy cardiomyocytes, but had no obvious positive effect on the cardiomyocytes of hypertensive rats, PA enhanced the contractility of cardiomyocytes by increasing ATP level in them, and the inhibitory effect of PA on myocardial contractility in hypertensive rats may be related to the increased nNOS and CPT-1 in cardiomyocytes.

1. Introduction

Cardiovascular disease is a serious threat to human health, which accounts for about thirty percent of global deaths. Hypertension refers to that systolic blood pressure or diastolic blood pressure is increased in resting state, often accompanied with the disorder of adipose and glucose metabolism and the functional or organic change of heart, brain, nerve, and retina. Hypertension-related cardiovascular complications are one of the leading causes of premature death worldwide. Hypertension is a global multiple disease, the prevalence of the elderly is increasing year by year, and hypertrophy of the cardiac muscle caused by constant stress overload is a bad outcome of it. Hypertension can cause...
changes in myocardial energy metabolism, and these changes rapidly reduce the oxidation rate of fatty acids and its enzymatic expression and activity [1–3].

Energy supply to myocardium in healthy adults mainly comes from fatty acid and glucose oxidation. Fatty acid is the preferred substrate for cardiomyocytes, accounting for 65% of the total ATP supply, while glucose and lactic acid provide 35% of the energy required by cardiomyocytes. Palmitic acid (PA) is the most abundant free saturated fatty acid in plasma lipids and widely exists in animal and vegetable oils in the form of glycerides [4, 5] and is a type of fatty acid and is a major cardiometabolic substrate. The concentration of free fatty acids in the plasma is an important determinant of the heart’s fat uptake rate. In healthy people, the concentration range is 0.2–0.6 mm, which is higher under severe cardiac load [6–8]. Studies showed that carbon monoxide could regulate myocardial strength, promote myocardial relaxation, and play an important role in maintaining cardiac function. Calcium-free table solution (in mmol/L: 140 NaCl, 5.4 KCl, 0.33 NaH₂PO₄, 10 HEPES, 10 Glucose, 1 MgCl₂, pH = 7.40) was used as perfusion fluid first. Colagenase II solution was used for perfusion (37°C, about 10 min) after the perfusion fluid was generally colorless. Then, the left ventricle was clipped and digested in a preset 37°C collagenase II solution containing 1 mg/mL collagenase, 1.67 mg/mL BSA, and 50 μM CaCl₂ separation solution (10G/min in a constant temperature shaker) for 10 min. The upper cell suspension was absorbed and centrifuged at 33G/min for 3 min, and the supernatant was discarded. Then, the preservation solution (in mmol/L: 70 KOH, 50 L-glutamate, 55 KCl, 20 taurine, 20 KH₂PO₄, 3 MgCl₂) was added. The cells were stored at room temperature and used within 8 h of separation.

2. Materials and Methods

2.1. Materials. The materials are mini osmotic pump (American Health Medical Instruments International), blood pressure meter (OMRON, Japan), IonOPTIX (American IonOPTI company), bechtop (Suzhou Su Clean), inverted microscope (Olympus, Japan), HVE-50 autoclave (Hirayama, Japan), PA (Ca#H8780-100g, Solarbio Biological Co., Ltd.), bovine serum albumin (Albumin Bovine V, BSA, Biosharp-100G), and specific nNOS inhibitor (S-methyL-thiocitrulline, SMTC) (100 μM). L-VNIO (vinyl-L-N-5-(1-imino-3-butenyl)-L-ornithine) is a NOSI inhibitor.

2.2. Establishment of Rat Model. Healthy male Sprague–Dawley (SD) rats, provided by the Experimental Animal Center of S University, with body mass of 200–250 g, were randomly divided into the sham operation group and the hypertension group, with thirty rats in each group. Hypertension group: angiotensin II-induced hypertension model was established. Angiotensin II (AngII) was delivered using a miniature osmotic pump (HMS International, USA) at a rate of 125 ng/min/kg, the rats were injected with it for 4 weeks, and the osmotic pump was placed into the subcutaneous tissue behind the back and neck. Sham operation group: the subcutaneous tissues behind the back and neck were separated after respiratory anesthesia with the same method, but no capsule osmotic pressure pump was put in, namely, the sham operation group. The blood pressure of rats was monitored every other day by the noninvasive blood pressure system of Kent Coda, USA, using the multianimal multichannel caudal cuff method from 1 day before randomization. At the end of the 4th week, the heart was removed under anesthesia, and the myocytes were isolated immediately.

Preparation of PA: 25.6 mg PA was dissolved in 1 mL anhydrous ethanol (100 mmol/L). After the PA was completely dissolved, it was stored separately in the -20°C refrigerator. BSA with different saturated fatty acids was prepared into 10× working solution (1 mmol/L), which was shaken in water bath at 40°C, then mixed and dissolved, filtered and sterilized with 0.22 μm filter membrane, and stored at 4°C for later use. The drug groups were as follows: 1 μM group, 10 μM group, 50 μM group, and 100 μM group of PA were set, respectively, in the two groups. The research content of this project strictly followed the Declaration of Helsinki, and the project had been approved by the Ethics Committee of The Affiliated Hospital of S University.

2.3. Isolation of Myocardial Cells. Intraperitoneal injection of sodium pentobarbital (30 mg/kg, i.p.) was made. After anesthesia, the hearts of the rats were removed, the aorta was intubated immediately, and the hearts were placed under the Langendorff device. Calcium-free table solution (in mmol/L: 140 NaCl, 5.4 KCl, 0.33 NaH₂PO₄, 10 HEPES, 10 Glucose, 1 MgCl₂, pH = 7.40) was used as perfusion fluid first. Colagenase II solution was used for perfusion (37°C, about 10 min) after the perfusion fluid was generally colorless. Then, the left ventricle was clipped and digested in a preset 37°C collagenase II solution containing 1 mg/mL collagenase, 1.67 mg/mL BSA, and 50 μM CaCl₂ separation solution (10G/min in a constant temperature shaker) for 10 min. The upper cell suspension was absorbed and centrifuged at 33G/min for 3 min, and the supernatant was discarded. Then, the preservation solution (in mmol/L: 70 KOH, 50 L-glutamate, 55 KCl, 20 taurine, 20 KH₂PO₄, 3 MgCl₂, 20 Glucose, 10 HEPES, 0.5 EGTA, pH = 7.30) was added. The cells were stored at room temperature and used within 8 h of separation.
2.4. Tail-Cuff Method for Measuring Blood Pressure. Blood pressure values of sham group and hypertension group were measured at 1, 2, 3, and 4 weeks after treatment. The rats were placed on a heating pad at 37°C for 15 minutes, and the systolic pressure was read between the tail sleeve and the standard device of the pulse sensor. The tail sleeve was connected to the compressed air cylinder by arrangement of the inlet and outlet valves to allow constant inflation and deflation of the cuff, and the cuff pressure was continuously recorded with a fixed pressure sensor. The signals from the pulse and pressure sensors were appropriately amplified, and then, the signals were digitized with an analog-digital board installed in the computer. The appropriate software was used to obtain online display of the control program and files for subsequent processing, the indirect blood pressure during the cycle of inflation and deflation was always recorded, and the time interval was changed between cycles as needed.

2.5. Measurement of Contractility of Left Ventricular Cardiomyocytes. The inverted microscope had a cell-infusion chamber on the platform, and the isolated cardiomyocytes were placed into the chamber. After cell precipitation, 2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid HEPES buffer infusion (141.4 NaCl, 4 KCl, 0.33 NaH2PO4, 10 HEPES, 5 Glucose, 14.5 mannitol, 1.8 CaCl2, 1 MgCl2, in mM) was passed through the chamber at a rate of 1 mL/min. The temperature was heated to 36 ± 1°C, and the flow rate was constant from the right port. Cells were stimulated by electrodes on both sides of the chamber with...
a stimulation voltage of 10 V and a frequency of 2 Hz. The cell shrinkage image was transmitted to IonOptix’s MyoCam camera system via a 40× objective lens and displayed on the monitor. The data were analyzed offline, averaging at least 10 measurements of stable contraction per cell.

2.6. Determination of ATP Levels. Luminescence was used to determine the level of ATP in left ventricular cardiomyocytes. Left ventricular cardiomyocytes were incubated in HEPES buffer, and protein content was determined by Bicinchoninic acid (BCA) assay. After adding 50 μL of mammalian cell lysate to a microplate with 100 μL of cell suspension in each well, the plate was shaken at 700 rpm on an orbital shaker for 5 minutes. 50 μL of the substrate solution was added to the well and then placed on an orbital shaker to shake the plate at 700 rpm for 5 minutes. The luminescence was measured after the plate was placed in the dark and adapted for 10 minutes. The absorbance of the mixture was measured with a microplate reader, the standard ATP buffer was taken, and a dilution was prepared in water to make the concentration from 1×10⁻⁵ M to blank.

2.7. Western Blot. The isolated rat cardiomyocytes were used for protein extraction, and the protein concentration was measured by BCA assay. 30 μg of sample protein was taken and separated with sodium dodecyl sulfate polyacrylamide gel electrophoresis. The protein bands were transferred to polyvinylidene fluoride membrane by wet transfer assay and then blocked with 5% bovine serum albumin for 1 hour. Then, nNOS antibody was added and incubated for 2 hours at room temperature and rinsed 3 times with TBS + Tween (TBST) (1 L distilled water with NaCl 8 g, KCl 0.2 g, Tris base 3 g, pH = 7.4, Tween 20 plus 1 mL). Then, the corresponding secondary antibody was added, incubated for 1 h, and rinsed 3 times with TBST. Electrochemical optics darkroom exposure was conducted, the film showed protein bands after washing. Then, ImageJ was adopted to analyze the band abundance for subsequent comparative analysis.

2.8. Statistical Analysis. SPSS22.0 statistical software was used for data analysis, the chi-square test was used to compare the probabilities between the two groups, t-test was used to compare the mean between the two groups, one-way ANOVA and Turkey method were used for pairwise comparison of the mean values of multiple groups, and P < 0.05 was considered statistically significant.

3. Results

3.1. Determination of Blood Pressure. As shown in Figure 1, the blood pressure increased steadily in the first week. As time went by, the blood pressure of the hypertension group increased significantly. At the end of the fourth week, the systolic and diastolic blood pressure of the hypertension group were 158 mmHg and 129 mmHg, respectively, and the sham group were 114 mmHg and 92 mmHg.

3.2. Effects of Different Concentrations of PA on Myocardial Contractility of Normal Hearts. How the contractility of left ventricular cardiomyocytes changed in normal rats with PA supplementation was studied. As shown in Figure 2, with the increase of PA concentration, the extent of left ventricular cardiomyocyte sarcomere of healthy rats also increased. In the sham group, when the PA concentration was 0 μM, the sarcomere shortening in cardiomyocytes was 0.09 ± 0.003 μm; when the concentration of PA was 1 μM, the sarcomere shortening in cardiomyocytes was 0.111 ± 0.003 μm (P = 0.02, compared with that treated with 0 μM PA); when PA concentration was 20 μM, the sarcomere shortening in cardiomyocytes was 0.128 ± 0.002 μm (P = 0.02, compared with that treated with 0 μM PA); and when PA concentration was 100 μM, the sarcomere shortening in cardiomyocytes was 0.181 ± 0.002 μm (P = 0.02, compared with that treated with 0 μM PA).

![Figure 2: The effect of different concentrations of PA on myocardial contractility in normal rats.](image-url)
100 μM, the sarcomere shortening in cardiomyocytes was 0.163 ± 0.003 μm ($P < 0.05$, compared with that treated with 0 μM PA).

3.3. Effects of PA and ETO on the Contraction of Cardiomyocytes in Normal and Hypertensive Rats. ETO is carnitine acyltransferase 1 (CPT-1) inhibitor, and carnitine acyltransferase 1 is the rate-limiting enzyme of fatty acid oxidation, when it is blocked, the oxidative decomposition of fat is weakened. As shown in Figure 3(a), PA significantly increased the sarcomere shortening in the sham group ($P < 0.05$), and PA had no positive inotropic effect on the cardiomyocytes of hypertensive rats compared with the sham group. As shown in Figure 3(b), ETO treatment inhibited the positive muscle strength of PA in the sham group. With or without ETO, PA had no effect on contractility of cardiomyocytes in hypertensive rats.

3.4. The Relationship between the Positive Inotropic Effect Induced by PA and the Level of ATP in Cardiomyocytes. As shown in Figure 4, according to the in vitro analysis of ATP level in left ventricular cardiomyocytes, PA increased ATP level in sham group rats ($P = 0.01$), yet ATP level was not increased in hypertensive rats ($P = 0.53$). The data showed that in the sham group, PA increased myocardial contractility by increasing ATP levels in cardiomyocytes. The direct source of energy for muscle contraction in the heart was ATP, which broke down to produce energy, some of which...
was converted to mechanical work when the heart muscle contracted, and disturbance of ATP production can directly affect the contraction of the heart.

3.5. Effect of nNOS on Myocardial Contractility of PA-Induced Hypertension. As shown in Figure 5(a), compared with the sham group, nNOS protein in the left ventricular cardiomyocytes of the hypertensive rats was significantly increased. The expression of nNOS was significantly reduced after the addition of nNOS inhibitors SMTC and L-VNIO. As shown in Figure 5(b), nNOS-specific inhibitor SMTC was used to inhibit the expression of nNOS, based on which the sarcomere shortening of left ventricular cardiomyocytes was measured when PA was not given (0.090 ± 0.003 μm) and when PA was given (0.135 ± 0.003 μm), and it was found that SMTC restored the positive inotropic effect of PA in the hypertensive group rats. The expression of nNOS was inhibited by another nNOS inhibitor L-VNIO, the sarcomere shortening of cardiomyocytes was measured before (0.126 ± 0.003 μm) and after (0.147 ± 0.003 μm) PA administration, and the same results were observed. These results showed that increased nNOS in left ventricular cardiomyocytes under hypertension can reduce the dependence of PA increase in left ventricular cardiomyocytes of hypertensive rats (P < 0.001).

3.6. The Combined Effect of nNOS and CPT-1 on Myocardial Contractility of PA-Induced Hypertension. As shown in Figure 6, nNOS inhibitor SMTC and the CPT-1 inhibitor ETO were given at the same time, and the effects of PA on left
ventricular cardiomyocytes contractility in hypertensive rats were studied. The sarcomere shortening of cardiomyocytes pretreated with SMTC+ETO (0.092 ± 0.001 μm) and the sarcomere shortening of cardiomyocytes pretreated with SMTC+ETO (0.087 ± 0.003 μm) were measured, respectively. It was found that giving the nNOS inhibitor and CPT-1 inhibitors at the same time could inhibit the positive inotropic effect of PA on left ventricular cardiomyocytes in hypertension group rats (P = 0.49), which indicated that the increased nNOS in hypertensive rats inhibited the positive inotropic effect of PA on cardiomyocytes and was related to protein CPT-1.

4. Discussion

The heart is one of the organs with the greatest metabolic demand in the human body, and PA is one of the most common long-chain saturated FA in myocardial energetics. After fatty acids enter the heart’s cardiomyocytes through the FA transporter on the cell membrane, they are lipidated into long-chain fatty acyl-CoA and shuttle into the mitochondrial matrix after CPT-1 forms long-chain acylcarnitine. The ester acyl carnitine on the inner mitochondrial membrane is converted back to fatty acyl CoA through CPT and enters the fatty acid to produce ATP. The heart’s preferred substrate for oxidative metabolism is fatty acids. PA, also known as PA, is a saturated fatty acid [11]. It was found that with the increase of PA concentration, the sarcomere shortening in left ventricular cardiomyocytes of healthy rats increased. The results showed that PA had positive inotropic effect on healthy rat cardiomyocytes, yet PA did not have positive inotropic effects in left ventricular cardiomyocytes of hypertensive rats, which may be due to inhibition of fatty acid oxidation in hypertensive rat hearts, with the reduction of PA oxidation, myocardial metabolism would be more dependent on glucose as the substrate for energy supply [12].

In this study, the blood pressure rose steadily in the first week, and the blood pressure of the hypertension group increased significantly, indicating that the modeling was successful. In the sham group, the systolic blood pressure increased in the second week, and the intensity of the ejection of blood from the left ventricle to the aorta may increase when the heart contracted. The formation of blood pressure was related to the degree of blood filling in the circulatory system. The diastolic blood pressure in the third week may increase due to the elasticity of the aorta and aorta. After the two groups of rats were given PA, it was found that the shortened length of myocardial cell sarcomere in the sham group increased significantly, while the shortened length of the left ventricular myocardial cell sarcomere in the hypertension group did not change notably. It showed that the increased nNOS in hypertensive rats inhibited the positive inotropic effect of PA on cardiomyocytes and was related to the protein CPT-1 [13, 14].

Nitric oxide is an important autocrine and paracrine signaling molecule and plays a vital role in the regulation of cardiovascular physiology and pathology. Lack of nitric oxide is associated with oxidative stress, diastolic dysfunction, and most cardiovascular diseases. Nitric oxide is produced by nNOS in designated regions and affects downstream targets [15, 16]. The increased expression of nNOS in the cardiomyocytes of hypertensive rats prompted us to investigate whether nNOS was involved in the regulation of PA on myocardial contractility in the hypertensive group. After PA supplementation, nNOS inhibitors SMTC and L-VNIO were added to the left ventricular cardiomyocytes of the hypertensive group rats, and the contractility was significantly increased. Studies revealed that nNOS can affect myocardial function by regulating mitochondrial proteins, reduced mitochondrial oxygen consumption, and affected cardiac metabolism. Therefore, the use of nNOS together with other inhibitors of mitochondrial protein can inhibit the positive inotropic effect of PA in the cardiomyocytes of hypertensive rats.

The results showed that nNOS reduced the PA dependence of left ventricular cardiomyocytes in hypertensive rats. Research showed that CPT-1 was an important speed limit enzyme in the process of fatty acid oxidation, and ETO was the inhibitor of CPT-1. After ETO was used, the oxidative decomposition of fatty acid was weakened. In healthy rats, PA increased the myocardial contractility, which could be blocked by ETO [17, 18]. In hypertensive rats, the effect of PA on the myocardial contractility disappeared, yet nNOS activity of protein expression was raised, and administration of nNOS inhibitor and CPT-1 inhibitor could inhibit the positive inotropic effect of PA on left ventricular cardiomyocytes in hypertensive rats, which meant that increased nNOS in hypertensive rats inhibited the positive inotropic effect of PA on cardiomyocytes, and it was related to protein of CPT-1.

5. Conclusion

In this work, the hypertension model was constructed to study the effect of PA on myocardial cell contraction. The
results showed that PA-dependent metabolism was an important regulator of myocardial contraction in healthy rats and hypertensive rats. The increased nNOS in left ventricular cardiomyocytes under hypertension can control the positive inotropic effect of PA through the participation of CPT-1 inhibitors, thereby reducing the dependence of left ventricular cardiomyocyte contraction on PA in hypertensive rats. This work provides reference for clinical research on the relationship between cardiac capacity metabolism and cardiac function and also provides different therapeutic targets for in-depth study of the mechanism of FA on cardiomyocyte contractility in healthy and diseased hearts, which has important clinical significance.

Data Availability
Some or all data, models, or code generated or used during the study are available from the corresponding author by request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] S. Fatima, X. Hu, R. H. Gong et al., "Palmitic acid is an intracellular signaling molecule involved in disease development," Cellular and Molecular Life Sciences, vol. 76, no. 13, pp. 2547–2557, 2019.
[2] X. Lieben Louis, P. Raj, Z. Meikle et al., "Resveratrol prevents palmitic acid-induced cardiomyocyte contractile impairment," Canadian Journal of Physiology and Pharmacology, vol. 97, no. 12, pp. 1132–1140, 2019.
[3] Y. P. Chen, W. W. Kuo, R. Baskaran et al., "Acute hypoxic preconditioning prevents palmitic acid-induced cardiomyocyte apoptosis via switching metabolic GLUT4-glucose pathway back to CD36-fatty acid dependent," Journal of Cellular Biochemistry, vol. 119, no. 4, pp. 3363–3372, 2018.
[4] L. Adrian, M. Lenski, K. Tödter, J. Heeren, M. Böhm, and U. Laufs, "AMPK prevents palmitic acid-induced apoptosis and lipid accumulation in cardiomyocytes," Lipids, vol. 52, no. 9, pp. 737–750, 2017.
[5] Z. O. U. Yong and K. Min, "Tetrahydroxy stilbene glucoside alleviates PA-induced inflammation and apoptosis in cardiomyocytes by regulating miR-129-3p/Smad3 signaling," Cellular & Molecular Biology Letters, vol. 24, no. 1, 2019.
[6] Y. He, L. Zhou, Z. Fan, S. Liu, and W. Fang, "Palmitic acid, but not high-glucose, induced myocardial apoptosis is alleviated by _N_ -acetylcysteine due to attenuated mitochondrial-derived ROS accumulation-induced endoplasmic reticulum stress," Cell Death & Disease, vol. 9, no. 5, p. 568, 2018.
[7] Y. N. Wu, C. L. Jin, J. H. Jang, Z. H. Zhao, S. J. Kim, and Y. H. Zhang, "Reduced nNOS activity is responsible for impaired fatty acid-dependent mitochondrial oxygen consumption in atrial myocardium from hypertensive rat," Pflügers Archiv-European Journal of Physiology, vol. 472, 2020.
[8] C. L. Jin, M. Z. Yin, J. C. Paeng et al., "Neuronal nitric oxide synthase modulation of intracellular Ca2+ handling overrides fatty acid potentiation of cardiac inotropy in hypertensive rats," Pflügers Archiv-European Journal of Physiology, vol. 469, no. 10, pp. 1359–1371, 2017.
[9] C. L. Jin, Y. N. Wu, J. H. Jang et al., "Negligible effect of eNOS palmitoylation on fatty acid regulation of contraction in ventricular myocytes from healthy and hypertensive rats," PflügersArchiv-European Journal of Physiology, vol. 469, no. 9, pp. 1141–1149, 2017.
[10] I. Luptak, A. L. Sverdlov, M. Panagia et al., "Decreased ATP production and myocardial contractile reserve in metabolic heart disease," Journal of Molecular and Cellular Cardiology, vol. 116, pp. 106–114, 2018.
[11] E. M. Jeong, C. Z. Jin, J. H. Jang et al., "S-nitrosylation of transglutaminase 2 impairs fatty acid-stimulated contraction in hypertensive cardiomyocytes," Experimental & Molecular Medicine, vol. 50, no. 4, pp. 1–11, 2018.
[12] C. Farah, L. Y. M. Michel, and J. L. Balligand, "Nitric oxide signaling in cardiovascular health and disease," Nature Reviews Cardiology, vol. 15, no. 5, pp. 292–316, 2018.
[13] S. Karbasforush, A. Nourazarian, M. Darabi et al., "Docosahexaenoic acid reversed atherosclerotic changes in human endothelial cells induced by palmitic acid in vitro," Cell Biochemistry and Function, vol. 36, no. 4, pp. 203–211, 2018.
[14] G. Carta, E. Murru, S. Banni, and C. Manca, "Palmitic acid: physiological role, metabolism and nutritional implications," Frontiers in Physiology, vol. 8, p. 902, 2017.
[15] Y. Wang, X.-J. Wang, L.-M. Zhao et al., "Oxidative stress induced by palmitic acid modulates K_{Ca}2.3 channels in vascular endothelium," Experimental cell research, vol. 383, no. 2, p. 111552, 2019.
[16] S. K. Cheema, P. S. Tappia, and N. S. Dhalla, "Modification of gene expression in rat cardiomyocytes by linoleic and docosahexaenoic acids," Canadian Journal of Physiology and Pharmacology, vol. 97, no. 4, pp. 320–327, 2019.
[17] X. Zhang, X. C. Xue, Y. Wang et al., "Celastrol reverses palmitic acid-induced apoptosis via switching metabolic GLUT4-glucose pathway back to CD36-fatty acid dependent," Cell Biochemistry and Function, vol. 119, no. 4, pp. 3363–3372, 2018.